BT44
Based on 1 Customer Validation
BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.87%
- CAS. Nr.: 924759-42-2
- Formel: C28H27F4N3O4S
- Molecular Weight:577.59
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
BT44 (7.5-75 μM; 15 min) promotes RET phosphorylation and selectively activates downstream cascades in the cells expressing GFL receptors[1].
BT44 (0.5-10 μM; 16-20 h) promotes neurite outgrowth from sensory neurons[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:GFRα3-transfected MG87RET cells
-
Concentration:7.5, 18, 35 and 75 μM
-
Incubation Time:15 min
-
Result:Increased RET and ERK phosphorylation.
BT44 (12.5 or 25 mg/kg; s.c.; every second day for 10 days) protects IB4-positive neurons in DRGs of animals with experimental neuropathy[1].
BT44 (0.1 and 0.3 μg/24 h; infuse into the right dorsal striatum for 14 days) reverses amphetamine-induced motor imbalance and seems to protect dopaminergic fibers in the striatum in 6-OHDA rat model of Parkinson’s disease[2].
BT44 (10 mg/kg; i.v.) penetrates the blood-brain barrier and is rapidly eliminated from the circulation (half-life (t1/2) = 0.72 h) and brain (t1/2 = 0.47 h) in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats, spinal nerve ligation (SNL) and Streptozotocin (STZ; HY-13753)-induced diabetes mellitus models[1]
-
Dosage:5, 12.5 or 25 mg/kg
-
Administration:Subcutaneous injecton, every second day for 10, 42 or 14 days
-
Result:Alleviated mechanical allodynia in the SNL animals. Treatment with the dose of 5 mg/kg alleviated mechanical hyperalgesia in the STZ-treated animals, while the 12.5 mg/kg dose was not effective. Concentration of 5 mg/kg attenuated cold allodynia in the STZ-treated animals during the first two weeks while the effect of 12.5 mg/kg was not significant.
-
Animal Model:Wistar rats, SNL-induced diabetes mellitus model[1]
-
Dosage:12.5 or 25 mg/kg
-
Administration:Subcutaneous injecton, every second day for 10 days
-
Result:Led to a significant increase in the number of IB4 expressing neurons in the ipsilateral DRGs. The 12.5 mg/kg dose protected IB4-positive neurons from SNL-induced lesion.
Chemical Information
-
CAS. Nr. 924759-42-2
-
Appearance Solid
-
Molecular Weight 577.59
-
Formel C28H27F4N3O4S
-
Color White to off-white
-
SMILES
O=C(N1CCN(CC1)C2=CC(S(=O)(N3CC4=C(CC3)C=CC=C4)=O)=CC=C2OC)C5=CC=C(C=C5C(F)(F)F)F
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 62.5 mg/mL (108.21 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Viisanen H, et al. Novel RET agonist for the treatment of experimental neuropathies. Mol Pain. 2020 Jan-Dec;16:1744806920950866. [Content Brief]
[2]. Renko JM, et al. Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats. J Parkinsons Dis. 2021;11(3):1023-1046. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7313 mL | 8.6567 mL | 17.3133 mL | 43.2833 mL |
| 5 mM | 0.3463 mL | 1.7313 mL | 3.4627 mL | 8.6567 mL | |
| 10 mM | 0.1731 mL | 0.8657 mL | 1.7313 mL | 4.3283 mL | |
| 15 mM | 0.1154 mL | 0.5771 mL | 1.1542 mL | 2.8856 mL | |
| 20 mM | 0.0866 mL | 0.4328 mL | 0.8657 mL | 2.1642 mL | |
| 25 mM | 0.0693 mL | 0.3463 mL | 0.6925 mL | 1.7313 mL | |
| 30 mM | 0.0577 mL | 0.2886 mL | 0.5771 mL | 1.4428 mL | |
| 40 mM | 0.0433 mL | 0.2164 mL | 0.4328 mL | 1.0821 mL | |
| 50 mM | 0.0346 mL | 0.1731 mL | 0.3463 mL | 0.8657 mL | |
| 60 mM | 0.0289 mL | 0.1443 mL | 0.2886 mL | 0.7214 mL | |
| 80 mM | 0.0216 mL | 0.1082 mL | 0.2164 mL | 0.5410 mL | |
| 100 mM | 0.0173 mL | 0.0866 mL | 0.1731 mL | 0.4328 mL |